We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Olympus

Manufactures optical and digital equipment for the healthcare and consumer electronics sectors, including endoscopy a... read more Featured Products: More products

Download Mobile App




Novel Protein Biomarkers Identified for Prostate Cancer Aggressiveness

By LabMedica International staff writers
Posted on 05 Jan 2022
Prostate cancer is the most commonly diagnosed cancer in men and is among the top five causes of cancer-related death. More...
In most cases, prostate cancer can be successfully treated but there is a group of patients who suffer an aggressive course and often fatal outcome.

In order to be able to treat prostate cancer more efficiently, it is necessary to understand the complex processes in the tumor at the molecular level. Though multiple genomic and transcriptomic-based analyses have been conducted, the results have not yet contributed to an improvement of diagnostics and therapy of Prostate cancer (PCa) patients.

Clinical Scientist at the Medical University of Vienna (Vienna, Austria) and their colleagues acquired formalin-fixed and paraffin-embedded (FFPE) prostate material from 88 patients with primary PCa and seven patients with bladder cancer. Human tissue-microarray (TMA) generation as well as sample selection and preparation for laser microdissection were conducted.

Immunohistochemistry was conducted on FFPE TMAs using consecutive sections. Staining was performed using the BenchMark ULTRA automated staining system Ventana Medical Systems, Tucson, AZ USA). The samples were analyzed using an Olympus system (Tokyo, Japan). Proteomic Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) Analysis was also performed.

The investigators reported that retrospective data analysis identified 153 proteins differentially expressed between STAT3-low and STAT3-high samples. Out of these, 46 proteins were associated with mitochondrial processes including oxidative phosphorylation (OXPHOS), and 45 proteins were upregulated, including NDUFS1/ATP5O. In a STAT3 independent PCa cohort, high expression of NDUFS1/ATP5O was confirmed by immunocytochemistry (IHC) and was significantly associated with earlier biochemical recurrence (BCR). mRNA expression levels for these two genes were significantly higher in intra-epithelial neoplasia and in PCa compared to benign prostate glands. NDUFS1/ATP5O levels are increased both at the mRNA and protein level in aggressive PCa.

The authors noted that further analyses of the transcriptome, which comprises all genes that are transcribed in the cell at a certain point in time, also showed a rectified shift in the concentration of messenger ribonucleic acid (mRNA). This means that there is a direct correlation between the genetic transcripts and the proteins produced. The study represents an important step in establishing a link between NDUFS, ATP5O and cancer aggressiveness. NDUFS1 and ATP5O could therefore serve as additional immunohistochemical markers for aggressive prostate tumors and, at the same time, as new targets for cancer treatment. The study was published on November 30, 2021 in the journal Cancers.

Related Links:
Medical University of Vienna
Ventana Medical Systems
Olympus



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Drug Test Kit
DrugCheck 3000
New
Dopamine Assay
Dopamine ELISA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.